Engage Bio
Focus: Engage Bio is a pre-revenue biotech company specializing in Tethosome gene therapy technology targeting oncology and gene therapy indications. The company is in early-stage development with minimal clinical advancement to date.
Profile data last refreshed 4h ago · AI intelligence enriched 2mo ago
Open Jobs
1+1 this month
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Should You Work at Engage Bio?
AI assessmentHigh-risk, high-reward pre-revenue play best suited for mission-driven scientists and operational builders comfortable with existential uncertainty.
Why Work Here
- Ground-floor opportunity in novel Tethosome gene therapy platform with potential to establish foundational IP in emerging modality
- Focused pipeline in high-value oncology and genetic disease spaces with significant unmet medical need
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
G2019S LRRK2
Parkinson's DiseaseClinical Trials (1)
NCT04919356Parkinson's Disease G2019S LRRK2 Genetic Testing Program
N/AHelp build intelligence for Engage Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.